Premium
A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease
Author(s) -
Wong Kitty K.,
Alty Jane E.,
Goy Amanda G.,
Raghav Sanjay,
Reutens David C.,
Kempster Peter A.
Publication year - 2011
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.23687
Subject(s) - dyskinesia , levetiracetam , crossover study , parkinsonism , placebo , medicine , levodopa , parkinson's disease , randomized controlled trial , psychology , anesthesia , disease , psychiatry , epilepsy , pathology , alternative medicine
Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period. Results: Dyskinesia was slightly less on placebo ( P = .26). Patient diary records also showed less dyskinesia on placebo ( P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance ( P = .05). Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. © 2011 Movement Disorder Society